InsidersTradesSigma
Follow the Xenon Pharmaceuticals Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Xenon Pharmaceuticals Inc. has logged 37 insider filings. Market capitalisation: €6.2bn. The latest transaction was reported on 14 August 2026 (10 - Acquisition or disposition in the public market). Among the most active insiders: Machado, Patrick. All data is accessible without an account.
37
Insider Decl.
n/a
Thresholds
€104,160
2 ops.
Buy Volume
€1m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Xenon Pharmaceuticals Inc. Strong Buy (bullish), based on 19 analysts. Average price target: US$81.30.
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 14 August 2026
Declarations37 total
8,000 shares@ CA$64.055Common SharesTSXSEDI:4764860
Canonical exit: 9 Nov 2026 (T+90)
2,000 sharesCommon SharesTSXSEDI:4764859
Canonical exit: 9 Nov 2026 (T+90)
3,500 shares@ CA$7.38Common SharesTSXSEDI:4764858
3,500 sharesOptionsTSXSEDI:4764857
1,593 sharesRestricted Share UnitsTSXSEDI:4730770
10,507 sharesOptionsTSXSEDI:4730767
2,645 sharesCommon SharesTSXSEDI:4730761
2,645 sharesRestricted Share UnitsTSXSEDI:4730749
1,593 sharesRestricted Share UnitsTSXSEDI:4730740
10,507 sharesOptionsTSXSEDI:4730737
2,645 sharesCommon SharesTSXSEDI:4730724
Common SharesTSXSEDI:4730722
2,645 sharesRestricted Share UnitsTSXSEDI:4730720
1,190 shares@ US$52.990.0009% mcap100.0% of flowCommonSEC144:0001950047-26-005712
3,750 sharesCommon SharesSEC:0001193125-26-106727:0
3,750 sharesCommon SharesSEC:0001193125-26-106726:0
12,500 sharesCommon SharesSEC:0001193125-26-106724:0
7,500 sharesCommon SharesSEC:0001193125-26-102669:0
7,500 sharesCommon SharesSEC:0001193125-26-102667:0
75,000 shares@ US$8.4040.3% of flowCommon SharesSEC:0001193125-26-102666:0
40,000 shares@ US$7.4918.8% of flowCommon SharesSEC:0001193125-26-001172:0
14,375 shares@ US$45.03100.0% of flowCommon SharesSEC:0001193125-25-313147:0
2,500 shares@ US$30.8010.8% of flowCommon SharesSEC:0001209191-22-017418:0
25,000 shares@ US$8.40100.0% of flowCommon SharesSEC:0001209191-22-017316:0
1,234 shares@ US$3.679.7% of flowCommon SharesSEC:0001209191-22-017318:0
25 of 37 declarations
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company listed on the Nasdaq (XENE) in the United States, with offices in Vancouver, British Columbia, and Boston, Massachusetts. For French-speaking investors, Xenon is best viewed as a clinical-stage biotech rather than a mature commercial pharmaceutical company. Its stated mission is to discover, develop, and ultimately commercialize life-changing therapies for patients with significant unmet medical needs. ([investor.xenon-pharma.com](https://investor.xenon-pharma.com/)) The company’s roots are in ion-channel biology and medicinal chemistry, with discovery capabilities built on genetics of channelopathies. That scientific foundation has shaped a pipeline centered on potassium and sodium channel modulators. Xenon’s lead asset is azetukalner, a novel, selective Kv7 potassium channel opener. It is in Phase 3 development for epilepsy, including focal onset seizures, and is also being evaluated in major depressive disorder and bipolar depression. In addition, Xenon is advancing earlier-stage programs in pain, including Nav1.7 and Kv7 candidates in Phase 1. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1582313/000095017025058092/xene-2025-ars.pdf)) From a competitive standpoint, Xenon occupies an interesting niche in central nervous system drug development. Its strategy is to address high-burden neurological and neuropsychiatric disorders with a differentiated mechanism that could potentially support a first-in-class or best-in-class profile. This specialization may create meaningful upside if clinical data and regulatory execution remain strong. At the same time, the business is highly concentrated: the company’s own filings emphasize that it depends substantially on azetukalner and remains exposed to the classic risks of late-stage biotech, including clinical failure, enrollment delays, regulatory uncertainty, and future financing needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1582313/000095017025058092/xene-2025-ars.pdf)) Recent news has been materially positive. In March 2026, Xenon announced positive topline Phase 3 X-TOLE2 data in focal onset seizures. In April 2026, it presented additional Phase 3 and 48-month long-term data at the American Academy of Neurology annual meeting, reinforcing the clinical narrative around azetukalner. Earlier in 2026, management also disclosed a pro forma cash position of $716 million, including ATM proceeds, which it said extends the cash runway into the second half of 2027. ([investor.xenon-pharma.com](https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-positive-topline-data-phase-3-x-tole2-study?utm_source=openai)) Overall, Xenon Pharmaceuticals is a specialized U.S.-listed Nasdaq biotech with a focused neuroscience pipeline, a scientifically differentiated platform, and a near-term catalyst profile that remains heavily tied to azetukalner’s late-stage clinical and regulatory path. ([investor.xenon-pharma.com](https://investor.xenon-pharma.com/))
